Color-coded and picture labeling on topical psoriasis medications improved psoriasis patients’ knowledge and understanding of how to correctly use the medications, according to a study published April 10 in the Journal of Pharmacy and BioAllied Sciences.
MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.
Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.
Eli Lilly’s mirikizumab demonstrates superiority over secukinumab (Cosentyx, Novartis) as a treatment for moderate-to-severe plaque psoriasis, according to recently released results from the OASIS-2 study.
Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
An investigational topical phosphodiesterase (PDE)-4 inhibitor for psoriasis has demonstrated improvements on par with topical corticosteroids in phase 2b testing.
Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.
Using a novel autoantigen array, researchers have shown that the IgG4 anti-gliadin autoantibody might provide useful information for diagnosis and prognosis of psoriasis.
The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.
This episode dives into emerging research regarding probiotics specifically tailored to treat psoriasis and possibly other inflammatory skin diseases.
The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6<18 years in the European Union.
Cath O'Niell, chief scientific officer at SkinBioTherapeutics and professor of translational dermatology at the University of Manchester, discusses her recent research on developing probiotics to treat psoriasis and other inflammatory skin diseases.
Twice-weekly treatment with calcipotriene-betamethasone diproprionate provides safe and effective maintenance treatment for plaque psoriasis, according to phase 3 data.
Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
The U.S. Food and Drug Administration has approved Wynzora Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%, MC2 Therapeutics) for adult with plaque psoriasis. Wynzora is equipped with the MC2 Therapeutics’ patented PAD Technology and is currently under review in the EU.
Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.
The U.S. Food and Drug Administration has approved Mylan and Fujifilm Kyowa Kirin Biologics’ adalimumab-fkjp as a biosimilar to AbbVie’s adalimumab for a variety of inflammatory disease including plaque psoriasis and psoriatic arthritis.
A recently published review offers early insight into the risk and prognosis of COVID-19 in individuals receiving biologic therapy, providing recommendations for patient care and counseling.
Treatment with biologics may worsen infection risk, not prognosis, according to findings from a case-control study comprised of more than 10 million residents of the Lombardia region of Italy.
Case study finds no safety concerns, suggests possible benefit of apremilast for countering COVID-19 virus-induced inflammation.
Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.
With newer biologics consistently posting PASI improvements greater than 90%, dermatologists need to consider other factors when selecting a treatment. However, nuanced differences between the same drug class could be teased out, one expert says.
A recent study shows ixekizumab may be able to help treat moderate-to-severe cases of genital psoriasis.
A recent article shows oral apremilast may rapidly and significantly improve moderate-to-severe scalp psoriasis.
